Otsuka to fight Delamanid setback after CHMP red light
This article was originally published in Scrip
Executive Summary
Otsuka has suffered a setback after the European Medicines Agency' s Committee for Medicinal Products for Human Use (CHMP) declined to recommend the firm's Delamanid for multi-drug resistant TB. The committee said that the benefits of the drug had not been adequately shown.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.